SC 13G: Spyre Therapeutics, Inc.
Ticker: SYRE · Form: SC 13G · Filed: Oct 23, 2024 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | SC 13G |
| Filed Date | Oct 23, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Spyre Therapeutics, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Spyre Therapeutics, Inc. (ticker: SYRE) to the SEC on Oct 23, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ame of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 00773).
How long is this filing?
Spyre Therapeutics, Inc.'s SC 13G filing is 3 pages with approximately 940 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 940 words · 4 min read · ~3 pages · Grade level 7.7 · Accepted 2024-10-23 14:10:57
Key Financial Figures
- $0.0001 — ame of Issuer) Common stock, par value $0.0001 (Title of Class of Securities) 00773
Filing Documents
- deutsch_13g.htm (SC 13G) — 37KB
- 0001683168-24-007319.txt ( ) — 38KB
(a)
Item 1(a) Name of Issuer: Spyre Therapeutics, Inc.
(b)
Item 1(b) Address of Issuer’s Principal Executive Offices: 221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts 02453
(a)
Item 2(a) Name of Person Filing: Peter E. Deutsch
(b)
Item 2(b) Address of Principal Business Office or, if none, Residence: 25 East Pointe Lane, Old Greenwich, CT 06870.
(c)
Item 2(c) Citizenship: United States of America
(d)
Item 2(d) Title of Class of Securities: Common Stock, par value $0.0001
(e)
Item 2(e) CUSIP Number: 00773J202 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); (j) ¨ A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Page 4 of 5 Pages Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for the Reporting Person hereto and is incorporated herein by reference for such Reporting Person. The percentage set forth in Row 11 of this Schedule 13G is calculated based on 50,783,384 shares of common stock, par value $0.0001 per share, outstanding as of June 30, 2024, as reported in the Issuer’s Form 10-Q for the quarterly period ended June 30, 2024, filed with the SEC on August 7, 2024. Item 5. Not applicable. Item 6.